vs
PEOPLES BANCORP OF NORTH CAROLINA INC（PEBK）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是PEOPLES BANCORP OF NORTH CAROLINA INC的1.7倍（$35.5M vs $21.5M），PEOPLES BANCORP OF NORTH CAROLINA INC净利率更高（30.8% vs -304.2%，领先335.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 5.6%），PEOPLES BANCORP OF NORTH CAROLINA INC自由现金流更多（$20.0M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 4.2%）
美国北卡罗来纳州人民银行控股公司是一家区域性银行控股企业，总部位于美国北卡罗来纳州，主要面向当地居民、中小企业及社区机构提供个人与商业银行服务，涵盖存款账户、各类贷款、抵押业务及财富管理解决方案等。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
PEBK vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.5M | $35.5M |
| 净利润 | $6.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 40.7% | -304.8% |
| 净利率 | 30.8% | -304.2% |
| 营收同比 | 5.6% | 681.7% |
| 净利润同比 | 86.4% | 39.6% |
| 每股收益（稀释后） | $1.21 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $21.5M | $35.5M | ||
| Q3 25 | $21.4M | $5.2M | ||
| Q2 25 | $20.7M | $19.2M | ||
| Q1 25 | $20.0M | $14.7M | ||
| Q4 24 | $20.4M | $4.5M | ||
| Q3 24 | $20.5M | $26.1M | ||
| Q2 24 | $20.1M | $14.4M | ||
| Q1 24 | $19.8M | $13.8M |
| Q4 25 | $6.6M | $-108.1M | ||
| Q3 25 | $3.7M | $-162.3M | ||
| Q2 25 | $5.2M | $-171.9M | ||
| Q1 25 | $4.3M | $-202.5M | ||
| Q4 24 | $3.6M | $-178.9M | ||
| Q3 24 | $4.0M | $-95.8M | ||
| Q2 24 | $4.9M | $-97.5M | ||
| Q1 24 | $3.9M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 40.7% | -304.8% | ||
| Q3 25 | 22.4% | -3327.6% | ||
| Q2 25 | 32.2% | -916.8% | ||
| Q1 25 | 28.2% | -1297.9% | ||
| Q4 24 | 22.5% | -4042.4% | ||
| Q3 24 | 26.0% | -377.1% | ||
| Q2 24 | 31.3% | -697.4% | ||
| Q1 24 | 23.9% | -698.4% |
| Q4 25 | 30.8% | -304.2% | ||
| Q3 25 | 17.2% | -3135.3% | ||
| Q2 25 | 24.9% | -894.2% | ||
| Q1 25 | 21.8% | -1373.3% | ||
| Q4 24 | 17.5% | -3935.5% | ||
| Q3 24 | 19.3% | -367.5% | ||
| Q2 24 | 24.4% | -676.6% | ||
| Q1 24 | 19.9% | -662.4% |
| Q4 25 | $1.21 | $-0.17 | ||
| Q3 25 | $0.67 | $-0.36 | ||
| Q2 25 | $0.95 | $-0.41 | ||
| Q1 25 | $0.79 | $-0.50 | ||
| Q4 24 | $0.65 | $-0.56 | ||
| Q3 24 | $0.72 | $-0.34 | ||
| Q2 24 | $0.89 | $-0.40 | ||
| Q1 24 | $0.72 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $157.1M | $1.1B |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $58.1M | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | $59.3M | $594.4M | ||
| Q3 24 | $73.2M | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $157.1M | $1.1B | ||
| Q3 25 | $149.5M | $1.0B | ||
| Q2 25 | $144.0M | $919.1M | ||
| Q1 25 | $138.5M | $933.9M | ||
| Q4 24 | $130.6M | $1.0B | ||
| Q3 24 | $136.3M | $524.6M | ||
| Q2 24 | $124.3M | $584.4M | ||
| Q1 24 | $121.1M | $401.2M |
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.7B | $726.5M | ||
| Q2 24 | $1.7B | $775.9M | ||
| Q1 24 | $1.7B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $20.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | 92.7% | -133.1% |
| 资本支出强度资本支出/营收 | 6.6% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.22× | — |
| 过去12个月自由现金流最近4个季度 | $34.9M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $21.4M | $-46.1M | ||
| Q3 25 | $4.7M | $-117.4M | ||
| Q2 25 | $5.5M | $-76.4M | ||
| Q1 25 | $5.9M | $-132.0M | ||
| Q4 24 | $20.6M | $-115.4M | ||
| Q3 24 | $4.9M | $-59.2M | ||
| Q2 24 | $6.7M | $-82.2M | ||
| Q1 24 | $3.7M | $-102.3M |
| Q4 25 | $20.0M | $-47.3M | ||
| Q3 25 | $4.4M | $-117.6M | ||
| Q2 25 | $5.4M | $-79.6M | ||
| Q1 25 | $5.2M | $-133.8M | ||
| Q4 24 | $20.0M | $-116.7M | ||
| Q3 24 | $4.7M | $-63.8M | ||
| Q2 24 | $6.6M | $-83.4M | ||
| Q1 24 | $3.5M | $-109.0M |
| Q4 25 | 92.7% | -133.1% | ||
| Q3 25 | 20.4% | -2272.5% | ||
| Q2 25 | 25.9% | -413.9% | ||
| Q1 25 | 25.8% | -907.4% | ||
| Q4 24 | 98.0% | -2567.7% | ||
| Q3 24 | 22.9% | -244.6% | ||
| Q2 24 | 32.7% | -578.5% | ||
| Q1 24 | 17.9% | -789.9% |
| Q4 25 | 6.6% | 3.5% | ||
| Q3 25 | 1.5% | 4.7% | ||
| Q2 25 | 0.5% | 16.4% | ||
| Q1 25 | 3.8% | 12.4% | ||
| Q4 24 | 2.9% | 28.6% | ||
| Q3 24 | 1.0% | 17.5% | ||
| Q2 24 | 0.4% | 8.2% | ||
| Q1 24 | 0.6% | 48.2% |
| Q4 25 | 3.22× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
